What question did this study set out to answer?

This study aims to compare glycemic outcomes, specifically HbA1c and GMI reduction, between CGM-naïve and experienced diabetic patients.

June 7, 2026Diabetes

1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compares glycemic outcomes in CGM-naïve and experienced patients using implantable sensors, suggesting beneficial transitions.

This study aims to compare glycemic outcomes, specifically HbA1c and GMI reduction, between CGM-naïve and experienced diabetic patients.
Single-center study conducted over 14 months from Nov 2024 to Dec 2025
Analyzed n = 44 diabetic patients with specific wear time and device duration criteria
Used paired t-tests to assess significance at 3 and 6 months
Cohort baseline HbA1c was 7.85% ± 1.94%; naïve patients had 8.88% ± 2.83%
At 3 months, mean HbA1c reduction was 0.72% (p = 0.0068); naïve patients had 1.57% reduction, experienced had 0.53% (p = 0.0174)
Post-initiation mean GMI at 2 weeks was 6.79% ± 0.49% with overall significant reductions in HbA1c and GMI.

TANDON et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial compares glycemic outcomes in CGM-naïve and experienced patients using implantable sensors, suggesting beneficial transitions.